

Table E1: Characteristics of study volunteers and treatment requirements at the time of entry into the study.

Subjects	Patient	Age (yr)	Sex	Smoking status	Atopy (SPT) DP F P BG	Treatment AH CS IT	Asthma
<i>Control</i>	1	22	F	Never smoker	- - - -	- - -	-
	2	48	F	Never smoker	- - - -	- - -	-
	3	24	F	Never smoker	- - - -	- - -	-
	4	31	M	Never smoker	- - - -	- - -	-
	5	39	M	Never smoker	- - - -	- - -	-
	6	22	M	Never smoker	- - - -	- - -	-
<i>Allergic rhinitis</i>	7	28	M	Former smoker	+ - - -	- - -	-
	8	42	F	Never smoker	+ - - -	- - -	-
	9	23	F	Never smoker	+ - - -	- - -	-
	10	27	F	Never smoker	+ - - -	- - -	-
	11	34	F	Never smoker	+ - - -	- - -	+
<i>Atopic Polyp</i>	12	43	F	Never smoker	+ - + +	- + -	+
	13	35	M	Former smoker	+ - + +	- - -	-
	14	33	M	Never smoker	- + - -	- + -	-
	15	43	M	Former smoker	+ - + +	- + -	+
<i>Non-atopic Polyp</i>	16	21	M	Former smoker	- - - -	- + -	-
	17	33	M	Former smoker	- - - -	- + -	-
	18	57	M	Former smoker	- - - -	- - -	-

SPT: Skin prick test; DP: *Dermatophagoides pteronyssinus*; P: pollen; F: fungus (*Aspergillus fumigatus* or *Alternaria alternata*); AH: antihistamines; CS: nasal corticosteroids; IT: immunotherapy.

Table E2: The primer pairs and Taqman probes for JNK₂ and NF- κ B p105 subunit.

Genes	Primers (5'-3')	Taqman Probes (5'-3')	GenBank accession number
GAPDH	AGAAGGCTGGGGCTCAT TTG	AGGGGCCATCCACAGTCTTC	NM_001256799
JNK2	CTGCGTCACCCATACATC ACTGTAAATTAGCTCTTT CCATTCTTCA	CCGAAGCAGAAGCCCCACCACCT CAA	NM_002752
NF-Kb p105 subunit	GTAAGTCTGGACCCAA GGACCTCTGTCATTCGTG CTTCC	CGGCTTCGCAAACCTGGGTATAC TTCATGT	NM_003998

JNK: c-june *N*-terminale kinase; NF- κ B: Nuclear factor- κ B.